These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 33402911)
1. A review of the safety of vaccines used in routine immunization in Africa. Yamoah P; Bangalee V; Oosthuizen F Afr Health Sci; 2020 Mar; 20(1):227-237. PubMed ID: 33402911 [TBL] [Abstract][Full Text] [Related]
2. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304 [TBL] [Abstract][Full Text] [Related]
3. Adverse Events Following Immunization in Brazil: Age of Child and Vaccine-Associated Risk Analysis Using Logistic Regression. Lopes SRC; Perin JLR; Prass TS; Carvalho SMD; Lessa SC; Dórea JG Int J Environ Res Public Health; 2018 Jun; 15(6):. PubMed ID: 29865181 [No Abstract] [Full Text] [Related]
4. Vaccines for measles, mumps, rubella, and varicella in children. Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V Cochrane Database Syst Rev; 2020 Apr; 4(4):CD004407. PubMed ID: 32309885 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a combined measles, mumps, rubella and varicella live vaccine (ProQuad ®) administered concomitantly with a booster dose of a hexavalent vaccine in 12-23-month-old infants. Deichmann KA; Ferrera G; Tran C; Thomas S; Eymin C; Baudin M Vaccine; 2015 May; 33(20):2379-86. PubMed ID: 25765966 [TBL] [Abstract][Full Text] [Related]
6. Use of the Australian Childhood Immunisation Register for vaccine safety data linkage. Gold M; Dugdale S; Woodman RJ; McCaul KA Vaccine; 2010 Jun; 28(26):4308-11. PubMed ID: 20430123 [TBL] [Abstract][Full Text] [Related]
7. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. Croce E; Hatz C; Jonker EF; Visser LG; Jaeger VK; Bühler S Vaccine; 2017 Mar; 35(9):1216-1226. PubMed ID: 28162821 [TBL] [Abstract][Full Text] [Related]
9. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau. Fisker AB; Ravn H; Rodrigues A; Østergaard MD; Bale C; Benn CS; Aaby P Vaccine; 2014 Jan; 32(5):598-605. PubMed ID: 24325827 [TBL] [Abstract][Full Text] [Related]
10. Safety of vaccines used for routine immunization in the United States: An updated systematic review and meta-analysis. Gidengil C; Goetz MB; Newberry S; Maglione M; Hall O; Larkin J; Motala A; Hempel S Vaccine; 2021 Jun; 39(28):3696-3716. PubMed ID: 34049735 [TBL] [Abstract][Full Text] [Related]
11. Adverse events associated with childhood vaccines other than pertussis and rubella. Summary of a report from the Institute of Medicine. Stratton KR; Howe CJ; Johnston RB JAMA; 1994 May; 271(20):1602-5. PubMed ID: 8182813 [TBL] [Abstract][Full Text] [Related]
12. Vaccine adverse events in a safety net healthcare system and a managed care organization. Narwaney KJ; Breslin K; Ross CA; Shoup JA; Wain KF; Weintraub ES; McNeil MM; Hambidge SJ Vaccine; 2017 Mar; 35(9):1335-1340. PubMed ID: 28185740 [TBL] [Abstract][Full Text] [Related]
13. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants. Madhi SA; Koen A; Cutland C; Groome M; Santos-Lima E Pediatr Infect Dis J; 2013 Aug; 32(8):889-97. PubMed ID: 23538523 [TBL] [Abstract][Full Text] [Related]
14. Vaccine adverse events reported during the first ten years (1998-2008) after introduction in the state of Rondonia, Brazil. Cunha MP; Dórea JG; Marques RC; Leão RS Biomed Res Int; 2013; 2013():853083. PubMed ID: 23509790 [TBL] [Abstract][Full Text] [Related]
16. Vaccines for measles, mumps, rubella, and varicella in children. Di Pietrantonj C; Rivetti A; Marchione P; Debalini MG; Demicheli V Cochrane Database Syst Rev; 2021 Nov; 11(11):CD004407. PubMed ID: 34806766 [TBL] [Abstract][Full Text] [Related]
17. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). Marin M; Broder KR; Temte JL; Snider DE; Seward JF; MMWR Recomm Rep; 2010 May; 59(RR-3):1-12. PubMed ID: 20448530 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. Nolan TM; Nissen MD; Naz A; Shepard J; Bedell L; Hohenboken M; Odrljin T; Dull PM Hum Vaccin Immunother; 2014; 10(2):280-9. PubMed ID: 24220326 [TBL] [Abstract][Full Text] [Related]
19. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017. Yoon D; Kim JH; Lee H; Shin JY Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206 [TBL] [Abstract][Full Text] [Related]
20. Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. Walker EJ; MacDonald NE; Islam N; Le Saux N; Top KA; Fell DB Vaccine; 2019 Mar; 37(13):1725-1735. PubMed ID: 30814030 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]